Genetic Diversity and Antiretroviral Drug Resistance among Drug-Naïve HIV-1 Infected Pregnant Women Attending Antenatal Clinics in Abidjan, Côte d'Ivoire

Loukou Yao Guillaume, Zinzendorf Nanga Yessé, Kouadio Hortense, Djé Laurent, Cablan Mian Arsher, Lathro Serge Joseph, Akoua Koffi Marie-Chantal

Faculty of Medical Sciences, University of Cocody, Abidjan, C?te d’Ivoire; Pasteur Institute, Abidjan, C?te d’Ivoire.
Faculty of Pharmaceutical and Biological Sciences, University of Cocody, Abidjan, C?te d’Ivoire.
Faculty of Pharmaceutical and Biological Sciences, University of Cocody, Abidjan, C?te d’Ivoire; National Public Health Laboratory, Abidjan, C?te d’Ivoire.

DOI: 10.4236/wja.2012.22008                

Abstract

To clarify the distribution of HIV-1 subtypes and drug resistance-related mutations, we collected and analysed serum from pregnant women who are ARV drug-naive in Abidjan. The prevalence of HIV-1 subtypes and mutations associated with antiretroviral drug resistance among drug-na?ve HIV-1 infected pregnant women was investigated from plasma of 90 young pregnant primigravida. The HIV-1 pol and env genes were amplified by using primers recognizing conserved viral sequences and sequenced by employing BigDye chemistry. Positions 1 - 99 of the PR and 1 - 350 of the RT genes were analyzed for mutations based on the international AIDS society USA panel. In 39 strains which both genes were sequenced including CFR02_AG 30 (76.9%), subtype A 3 (7.7%), CFR06_cpx 2 (5.1%), CFR09_cpx 1 (2.6%), and discordant sequences suggesting the presence of a few number of recombinant involving CRF02-AG and subtype A 3 (7.7%). None of the major drug resistance mutations was detected. The frequent minor mutations associated drug resistance observed were M36I (52%/96.3%), L10I/R/V (19%/35.2%) and L63P (7%/12.9%). The M36I mutation was widespread in all subtypes. Our result demonstrated first a significant level of viral heterogeneity and then only the presence of minor resistance associated mutations. Our study emphasizes the need of HIV sentinel survey in C?te d'Ivoire and shows that pregnant women who are candidates for receiving antiretroviral drug therapies do not contain naturally occurring or preexisting drug resistance mutations. So such drug therapies are likely to be highly effective in this setting.

Keywords

HIV-1; Drug Naïve Pregnant Women; ARV Resistance

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. L. Robertson, J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky and B. Korber, “HIV-1 Nomenclature Proposal,” Science, Vol. 288, No. 5463, 2000, pp. 55-56. doi:10.1126/science.288.5463.55d
[2]	M. Peeters, C. Toure-Kane and J. N. Nkengasong, “Genetic Diversity of HIV in Africa: Impact on Diagnosis, Treatment, Vaccine Development and Trials,” AIDS, Vol. 17, No. 18, 2003, pp. 2547-2560. doi:10.1097/00002030-200312050-00002
[3]	N. Vidal, C. Mulanga, S. E. Bazepeo, J .K. Mwamba, J. W. Tshimpaka, M. Kashi, N. Mama, C. Laurent, F. Lepira, E. Delaporte and M. Peeters, “Distribution of HIV-1 Variants in the Democratic Republic of Congo Suggests Increase of Subtype C in Kinshasa between 1997 and 2002,” Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 4, 2005, pp. 456-462. doi:10.1097/01.qai.0000159670.18326.94
[4]	S. Bertagnolio and D. Sutherland, “WHO Approach to Track HIV Drug Resistance Emergence and Transmission in Countries Scaling up HIV Treatment,” AIDS, Vol. 19, No. 12, 2005, pp. 1329-1330. doi:10.1097/01.aids.0000180107.19006.02
[5]	S. Toure, B. Kouadio, C. Seyler, M. Traore, N. Dakoury-Dogbo, J. Duvignac, N. Diakite, S. Karcher, C. Grundmann, R. Marlink, F. Dabis, X. Anglaret and Aconda Study Group, “Rapid Scaling-Up of Antiretroviral Therapy in 10,000 Adults in Cote d’ivoire: 2-Year Outcomes and Determinants,” AIDS, Vol. 22, No. 7, 2008, pp. 873-882. doi:10.1097/QAD.0b013e3282f768f8
[6]	A. Ayouba, T. T. Lien, J. Nouhin, L. Vergne, A. F. Aghokeng, N. Ngo-Giang-Huong, H. Diop, C. T. Kane, D. Valéa, F. Rouet, D. Joulia-Ekaza, T. D. Toni, E. Nerrienet, E. M. Ngole, E. Delaporte, D. Costagliola, M. Peeters and M. L. Chaix, “Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, C?te d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study,” AIDS Research Human Retroviruses, Vol. 25, No. 11, 2009, pp. 1193-1196. doi:10.1089/aid.20
[7]	L. Vergne, S. Diagbouga, C. Kouanfack, A. Aghokeng, C. Butel, C. Laurent, N. Noumssi, M. Tardy, A. Sawadogo, J. Drabo, H. Hien, L. Zekeng, E. Delaporte and M. Peeters, “HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon,” Antiviral Therapy, Vol. 11, No. 5, 2006, pp. 575-579.
[8]	J. D. Thompson, D. G. Higgins and T. J. Gibson, “CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice,” Nucleic Acids Research, Vol. 22, No. 22, 1994, pp. 4673-4680. doi:10.1093/nar/22.22.4673
[9]	T. Toni, B. Masquelier, A. Minga, X. Anglaret, C. Danel, A. Coulibaly, H. Chenal, F. Dabis, R. Salamon, H. J. Fleury and Primo-CI ANRS 1220 Study Group, “HIV-1 Antiretroviral Drug Resistance in Recently Infected Patients in Abidjan, C?te D'Ivoire: A 4-Year Survey, 2002- 2006,” AIDS Research and Human Retroviruses, Vol. 23, No. 9, 2007, pp. 1155-1160. doi:10.1089/aid.2007.0072
[10]	D. A. Yaotsè, V. Nicole, N. F. Roch, P. D. Mireille, D. Eric and P. Martine, “Genetic Characterization of HIV-1 Strains in Togo Reveals a High Genetic Complexity and Genotypic Drug-Resistance Mutations in ARV Naive Patients,” Infection, Genetic and Evolution, Vol. 9, No. 4, 2009, pp. 646-652. doi:10.1016/j.meegid.2009.04.002
[11]	J. L. Sankalé, S. Langevin, G. Odaibo, S. T. Meloni, A. I. Ojesina, D. Olaleye and P. Kanki, “The Complexity of Circulating HIV Type 1 Strains in Oyo State, Nigeria,” AIDS Research Human Retroviruses, Vol. 23, No. 8, 2007, pp. 1020-1025. doi:10.1089/aid.2006.0304
[12]	B. D. Preston, B. J. Poiesz and L. A. Loeb, “Fidelity of HIV-1 Reverse Transcriptase,” Science, Vol. 242, No. 4882, 1988, pp. 1168-1171. doi:10.1126/science.2460924
[13]	M. S. Hirsch, H. F. Günthard, J. M. Schapiro, F. Brun-Vézinet, B. Clotet, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, J. W. Mellors, D. Pillay, P. G. Yeni, D. M. Jacobsen and D.D. Richman, “Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2008 Recommendations of an International AIDS Society-USA Panel,” Clinical Infections Disease, Vol. 47, No. 2, 2008, pp. 266-285. doi:10.1086/589297
[14]	M. Tshabalala, J. Manasa, L. S. Zijenah, S. Rusakaniko, G. Kadzirange, M. Mucheche, S Kassaye, E. Johnston and D. Katzenstein, “Surveillance of Transmitted Antiretroviral Drug Resistance among HIV-1 Infected Women Attending Antenatal Clinics in Chitungwiza, Zimbabwe,” PLoS One, Vol. 6, No. 6. 2011, p. e21241.
[15]	H. Diop-Ndiaye, C. Toure-Kane, N. Leye, N. F. Ngom-Gueye, C. Montavon, M. Peeters and S. Mboup, “Antiretroviral Drug Resistance Mutations in Antiretroviral-Naive Patients from Senegal,” AIDS Research and Human Retroviruses, Vol. 26, No. 10, 2010, pp. 1133-1138. doi:10.1089/aid.2009.0295
[16]	R. L. Hamers, M. Siwale, C. L. Wallis, M. Labib, R. Van Hasselt, W. S. Stevens, R. Schuurman, A. M. Wensing, M. Van Vugt, T. F. Rinke De Wit and PharmAccess African Studies to Evaluate Resistance, “HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia,” Journal of Acquired Immune Deficiency Syndromes, Vol. 55, No. 1, 2010, pp. 95-101. doi:10.1097/QAI.0b013e3181e544e0
[17]	D. Pieniazek, M. Rayfield, D. J. Hu J. Nkengasong, S. Z. Wiktor, R. Downing, B. Biryahwaho, T. Mastro, A. Tanuri, V. Soriano, R. Lal and T. Dondero, “Protease sequences from HIV-1 Group M Subtypes A-H Reveal Distinct Amino Acid Mutation Patterns Associated with Protease Resistance in Protease Inhibitor-Naive Individuals Worldwide. HIV Variant Working Group,” AIDS, Vol. 14, No. 1, 2000, pp. 1489-1495. doi:10.1097/00002030-200007280-00004
[18]	L. Vergne, M. Peeters, E. Mpoudi-Ngole A. Bourgeois, F. Liegeois, C. Toure-Kane, S. Mboup, C. Mulanga-Kabeya, E. Saman, J. Jourdan, J. Reynes and E. Delaporte, “Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients,” Journal of Clinical Microbiology, Vol. 38, No. 11, 2000, pp. 3919-3925.
[19]	J. D. Church, S. E. Hudelson, L. A. Guay, S. Chen, D. R. Hoover, N. Parkin, S. A. Fiscus, F. Mmiro, P. Musoke, N. Kumwenda, J. B. Jackson, T. E. Taha and S. H. Eshleman. “HIV Type 1 Variant with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C and D,” AIDS Research and Human Retroviruses, Vol. 23, No. 6, 2007, pp. 764-768. doi:10.1089/aid.2006.0272
[20]	B. T. R?ge, T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren and J. Gerstoft, “K65R with and without S68: A New Resistance Profile in Vivo Detected in Most Patients Failing Abacavir, Didanosine and Stavudine,” Antiviral Therapy, Vol. 8, No. 2, 2003, pp. 173-182.
[21]	L. Romano, G. Venturi, S. Bloor, R. Harrigan, B. A. Larder, J. C. Major and M. Zazzi, “Broad Nucleoside-Analogue Resistance Implications for Human Immunodeficiency Virus Type 1 Reverse-Transcriptase Mutations at Codons 44 and 118,” Journal of Infections Diseases, Vol. 185, No. 7, 2002, pp. 898-904. doi:10.1086/339706
[22]	M. Girouard, K. Diallo, B. Marchand, S. McCormick and M. G?tte, “Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC,” Journal of Biological Chemistry, Vol. 278, No. 36, 2003, pp. 34403-34410. doi:10.1074/jbc.M303528200
[23]	E. Domingo and J. J. Holland, “Mutation Rates and Rapid Evolution of RNA Viruses,” In: S. S. Morse, Ed., The Evolutionary Biology of Viruses, Raven Press, New York, 1994, pp. 161-184.
[24]	W. M. Nadembega, S. Giannella, J. Simpore, F. Ceccherini-Silberstein, V. Pietra, A. Bertoli, S. Pignatelli, M. C. Bellocchi, J. B. Nikiema, G. Cappelli, A. Bere, V. Colizzi, C. P. Perno and S. Musumeci, “Characterization of Drug-Resistance Mutations in HIV-1 Isolates from Non-HAART and HAART Treated Patients in Burkina Faso,” Journal of Medical Virology, Vol. 78, No. 11, 2006, pp. 1385-1391. doi:10.1002/jmv.20709
[25]	R. M. Viani, K. Hsia, P. Hubbard, J. Ruiz-Calderon, R. Lozada, J. Alvelais, M. Gallardo and S. A. Spector, “Prevalence of Primary HIV-1 Drug Resistance in Pregnant Women and in Newly Diagnosed Adults at Tijuana General Hospital, Baja California, Mexico,” International Journal of STD & AIDS, Vol. 18, No. 4, 2007, pp. 235-238. doi:10.1258/095646207780658962
[26]	J. G. García-Lerma, P. J. Gerrish, A. C. Wright, S. H. Qari and H. Walid, “Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1,” Journal of Virology, Vol. 74, No. 20, 2000, pp. 9339-9346. doi:10.1128/JVI.74.20.9339-9346.2000
[27]	V. Miller, M. Ait-Khaled, C. Stone, P. Griffin, D. Mesogiti, A. Cutrell, R. Harrigan, S. Staszewski, C. Katlama, G. Pearce and M. Tisdale, “HIV-1 Reverse Transcriptase (RT) Genotype and Susceptibility to RT Inhibitors during Abacavir Monotherapy and Combination Therapy,” AIDS, Vol. 14, No. 2, 2000, pp. 163-171. doi:10.1097/00002030-200001280-00012